Elicio Therapeutics GAAP EPS of -$0.66

3 hours ago 1

Elicio Therapeutics press release (NASDAQ:ELTX): Q2 GAAP EPS of -$0.66.
Cash and cash equivalents, as of June 30, 2025, were $22.1 million.

The Company expects that its current cash and cash equivalents will support operations into Q1 2026, beyond the anticipated AMPLIFY-7P Phase 2 final analysis.

Recommended For You